Using Tomorrow's Medicines Today

Current Studies

Clinical Studies

Trailblazer
Alzheimer’s

Taurel
Alzheimer’s

AZT-001
Alzheimer’s

Embark
Alzheimer’s

BAN2401-201 OLE
Alzheimer’s

Clarity
Alzheimer’s

Graduate
Alzheimer’s

Mirror
Uncontrolled Gout

Alithios
Multiple Sclerosis

Exchange
Multiple Sclerosis

Novo Select
Cardiac

Sk Life Science
17/21 Seizures

PrecMed
Parkinson’s

PrecMed
Alzheimer’s

PrecMed
Multiple Sclerosis

ACT 4422g
Multiple Sclerosis

Trailblazer Alzheimers Study

This study will assess whether removal of existing amyloid plaque can slow the progression of Alzheimer’s in prodromal AD and mild dementia due to AD.

You may be able to take part in this study if you:

Tauriel Alzheimer’s Study

The TAURIEL Study will look at an investigational medication for people with Alzheimer’s disease. The study will help determine how safe the investigational medication is and whether or not it works in affecting Alzheimer’s disease.

The TAURIEL Study might be right for you if you:

AZT-001 Alzheimer’s Study

This clinical research trial is enrolling men and women who may have evidence of early stage Alzheimer’s disease. The clinical trial is evaluating whether a combined treatment slows down early stage Alzheimer’s disease.

Qualified participants must:

Embark Alzheimer’s Study

Subjects with Alzheimer’s disease who had previously participated in the Aducanumab studies.

Qualified participants must:

BAN2401-201OLE Alzheimer’s Study

This medical study is for people who are experiencing increasing problems with their memory that may be early symptoms of Alzheimer’s disease. This study will evaluate the effectiveness of an investigational product (study drug). You must have been enrolled in the double-blind study.

Qualified participants must:

Clarity Alzheimer’s Study

18-Month study with an open-label extension phase to confirm safety and efficacy of an investigational drug in subjects with early Alzheimer’s Disease.

Qualified participants must:

Graduate Alzheimer’s Study

Study With an Open-Label Extension Phase to Confirm Safety and Efficacy in subjects with early (prodromal to mild) Alzheimer’s.

Qualified participants must:

MIRROR Gout Study

A study testing efficacy and safety of two drugs to increase response rates in patients with Uncontrolled Gout.

Qualified participants must:

Alithios Multiple Sclerosis Study

An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of an investigational drug in subjects with relapsing multiple sclerosis.

Qualified participants must:

Exchange Multiple Sclerosis Study

An open label study exploring safety and tolerability of conversion to Oral Siponimod in patients with relapsing multiple sclerosis.

Qualified participants must:

Select Cardiac Study

Effects of Semaglutide on cardiovascular outcomes in people with overweight or obesity.

Qualified participants must:

SK Life Science 17/21 Seizure Study

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects with Partial Onset Seizures, with Optional Open-Label Extension.

Qualified participants must:

PrecMed Parkinson’s Study

The purpose of this medical study is to collect biological samples from subjects with Parkinson’s disease. The samples may contain substances that the researchers will be able to analyze to study their genetic, protein, and chemical composition. The study will look at blood and cerebrospinal fluid differences associated with Parkinson’s disease or with other aspects of the illness, such as response to medication and side effects. The cells from your blood may be retained as cell lines grown from your blood to be used in the future. The sample may assist in the development of a new drug treatment or a new diagnostic test for Parkinson’s disease. Your samples will be kept indefinitely by the sponsor.

PrecMed Alzheimer’s Study

The purpose of this medical study is to collect biological samples from subjects with Alzheimer’s disease. The samples may contain substances that the researchers will be able to analyze to study their genetic, protein, and chemical composition. The study will look at blood and cerebrospinal fluid differences associated with Alzheimer’s disease or with other aspects of the illness, such as response to medication and side effects. The cells from your blood may be retained as cell lines grown from your blood to be used in the future. The sample may assist in the development of a new drug treatment or a new diagnostic test for Alzheimer’s disease. Your samples will be kept indefinitely by the sponsor.

PrecMed Multiple Sclerosis Study

The purpose of this medical study is to collect biological samples from subjects with Multiple Sclerosis. The samples may contain substances that the researchers will be able to analyze to study their genetic, protein, and chemical composition. The study will look at blood and cerebrospinal fluid differences associated with Multiple Sclerosis or with other aspects of the illness, such as response to medication and side effects. The cells from your blood may be retained as cell lines grown from your blood to be used in the future. The sample may assist in the development of a new drug treatment or a new diagnostic test for Multiple Sclerosis. Your samples will be kept indefinitely by the sponsor.

ACT 4422g Multiple Sclerosis Study

Study to evaluate the efficacy as measured by brain MRI lesions and safety of 2 dose regimens of ocrelizumab in patients with RRMS.

Skip to content